Armata Pharmaceuticals Statistics
Armata Pharmaceuticals (TG1N) Stock Statistics & Valuation Metrics
Total Valuation
Armata Pharmaceuticals has a market cap or net worth of EUR 101.17M. The enterprise value is EUR 463.30M.
- Market Cap
- EUR 101.17M
- Enterprise Value
- EUR 463.30M
Share Statistics
Armata Pharmaceuticals has 37,192,630 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 37,192,630
- Owned by Insiders
- 0.60%
- Owned by Institutions
- 12.93%
Financial Efficiency
Armata Pharmaceuticals’s return on equity (ROE) is 0.80 and return on invested capital (ROIC) is -43.07%.
- Return on Equity (ROE)
- 0.80
- Return on Assets (ROA)
- -2.26
- Return on Invested Capital (ROIC)
- -43.07%
- Return on Capital Employed (ROCE)
- -0.46
- Revenue Per Employee
- 80.39K
- Profits Per Employee
- -2.85M
- Employee Count
- 61
- Asset Turnover
- 0.06
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Armata Pharmaceuticals is -0.73. Armata Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- -0.73
- PS Ratio
- 14.37
- PB Ratio
- 0.00
- Price to FCF
- -3.46
- Price to Operating Cash Flow
- -3.49
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Armata Pharmaceuticals had revenue of 4.90M and earned -173.80M in profits. Earnings per share was -4.80.
- Revenue
- 4.90M
- Gross Profit
- 3.37M
- Operating Income
- -31.22M
- Pretax Income
- -173.80M
- Net Income
- -173.80M
- EBITDA
- -155.68M
- Earnings Per Share (EPS)
- -4.80
Cash Flow
In the last 12 months, operating cash flow was -26.64M and capital expenditures -223,000, giving a free cash flow of -26.86M billion.
- Operating Cash Flow
- -26.64M
- Free Cash Flow
- -26.86M
- Free Cash Flow per Share
- -0.72
Dividends & Yields
Armata Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -27.05%
- Earnings Yield
- -111.45%
Stock Price Statistics
- Beta
- 1.51
- 52-Week Price Change
- -43.67%
- 50-Day Moving Average
- 3.29
- 200-Day Moving Average
- 5.89
- Relative Strength Index (RSI)
- 56.61
- Average Volume (3m)
- 370
Important Dates
Armata Pharmaceuticals upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Armata Pharmaceuticals as a current ratio of 1.19, with Debt / Equity ratio of -131.76%
- Current Ratio
- 1.19
- Quick Ratio
- 1.19
- Debt to Market Cap
- 1.13
- Net Debt to EBITDA
- -1.79
- Interest Coverage Ratio
- -1.88
Taxes
In the past 12 months, Armata Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Armata Pharmaceuticals EV to EBITDA ratio is -3.96, with an EV/FCF ratio of -12.38.
- EV to Sales
- 51.40
- EV to EBITDA
- -3.96
- EV to Free Cash Flow
- -12.38
- EV to Operating Cash Flow
- -12.48
Balance Sheet
Armata Pharmaceuticals has EUR 18.32M in cash and marketable securities with EUR 251.58M in debt, giving a net cash position of -EUR 233.27M billion.
- Cash & Marketable Securities
- EUR 18.32M
- Total Debt
- EUR 251.58M
- Net Cash
- -EUR 233.27M
- Net Cash Per Share
- -EUR 6.27
- Tangible Book Value Per Share
- -EUR 5.05
Margins
Gross margin is 74.96%, with operating margin of -622.92%, and net profit margin of -1710.14%.
- Gross Margin
- 74.96%
- Operating Margin
- -622.92%
- Pretax Margin
- -1710.14%
- Net Profit Margin
- -1710.14%
- EBITDA Margin
- -1298.61%
- EBIT Margin
- -1330.11%
Analyst Forecast
The average price target for Armata Pharmaceuticals is EUR 15.92, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 15.92
- Price Target Upside
- 371.02% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 43.97%
- EPS Growth Forecast
- -156.79%
Scores
- Smart Score
- 7
- AI Score
- ―

